Elesclomol has been identified as a new drug which may play a considerable role in melanoma. For over half a century, scientists studying cancer cells have often observed the Warburg affect, where cancer cells prevent normal energy-producing processes, "preventing them from using metabolis pathways in the cell's mitochondria." Elesclomol blocks the process of oxidative phosphorylation, which is seen as particularly viable for targeting early metastatic disease.
To read more about this study, published in PLoS One, click here.
Study mentioned: Barbi de Moura M et al. Mitochondrial respiration: An important therapeutic target in melanoma. PLoS One. 2012; 7(8):e40690. PMID 22912665
No comments:
Post a Comment